Background:There were few studies on real-world data about autologous hematopoietic stem cell transplantation(auto-HSCT)or allogeneic HSCT(allo-HSCT)in peripheral T-cell lymphoma(PTCL).This study aimed to investigate ...Background:There were few studies on real-world data about autologous hematopoietic stem cell transplantation(auto-HSCT)or allogeneic HSCT(allo-HSCT)in peripheral T-cell lymphoma(PTCL).This study aimed to investigate the clinical outcomes of patients who received auto-HSCT or allo-HSCT in China.Methods:From July 2007 to June 2017,a total of 128 patients who received auto-HSCT(n=72)or allo-HSCT(n=56)at eight medical centers across China were included in this study.We retrospectively collected their demographic and clinical data and compared the clinical outcomes between groups.Results:Patients receiving allo-HSCT were more likely to be diagnosed with stage III or IV disease(95%vs.82%,P=0.027),bone marrow involvement(42%vs.15%,P=0.001),chemotherapy-resistant disease(41%vs.8%,P=0.001),and progression disease(32%vs.4%,P<0.001)at transplantation than those receiving auto-HSCT.With a median follow-up of 30(2–143)months,3-year overall survival(OS)and progression-free survival(PFS)in the auto-HSCT group were 70%(48/63)and 59%(42/63),respectively.Three-year OS and PFS for allo-HSCT recipients were 46%(27/54)and 44%(29/54),respectively.There was no difference in relapse rate(34%[17/63]in auto-HSCT vs.29%[15/54]in allo-HSCT,P=0.840).Three-year non-relapse mortality rate in auto-HSCT recipients was 6%(4/63)compared with 27%(14/54)for allo-HSCT recipients(P=0.004).Subanalyses showed that patients with lower prognostic index scores for PTCL(PIT)who received auto-HSCT in an upfront setting had a better outcome than patients with higher PIT scores(3-year OS:85%vs.40%,P=0.003).Patients with complete remission(CR)undergoing auto-HSCT had better survival(3-year OS:88%vs.48%in allo-HSCT,P=0.008).For patients beyond CR,the outcome of patients who received allo-HSCT was similar to that in the atuo-HSCT group(3-year OS:51%vs.46%,P=0.300).Conclusions:Our study provided real-world data about auto-HSCT and allo-HSCT in China.Auto-HSCT seemed to be associated with better survival for patients in good condition(lower PIT score and/or better disease control).For patients possessing unfavorable characteristics,the survival of patients receiving allo-HSCT group was similar to that in the auto-HSCT group.展开更多
Long noncoding RNAs(lncRNAs)have recently been discovered and are increasingly recognized as vital components of modern molecular biology.Accumulating evidence shows that lncRNAs have emerged as important mediators in...Long noncoding RNAs(lncRNAs)have recently been discovered and are increasingly recognized as vital components of modern molecular biology.Accumulating evidence shows that lncRNAs have emerged as important mediators in diverse biological processes such as cell differentiation,pluripotency,and tumorigenesis,while the function of lncRNAs in the field of normal and malignant hematopoiesis remains to be further elucidated.Here,we widely reviewed recent advances and summarize the characteristics and basic mechanisms of lncRNAs and keep abreast of developments of lncRNAs within the field of normal and malignant hematopoiesis.Based on gene regulatory networks at different levels of lncRNAs participation,lncRNAs have been shown to regulate gene expression from epigenetics,transcription and post transcription.The expression of lncRNAs is highly cell-specific and critical for the development and activation of hematopoiesis.Moreover,we also summarized the role of lncRNAs involved in hematological malignancies in recent years.LncRNAs have been found to play an emerging role in normal and malignant hematopoiesis,which may provide novel ideas for the diagnosis and therapeutic targets of hematological diseases in the foreseeable future.展开更多
Akkermansia muciniphila(A.muciniphila),a type of Gram-negative anaerobe,was first isolated and identified from the feces of a healthy Caucasian woman at Wageningen University in 2004.[1]It can stably colonize the huma...Akkermansia muciniphila(A.muciniphila),a type of Gram-negative anaerobe,was first isolated and identified from the feces of a healthy Caucasian woman at Wageningen University in 2004.[1]It can stably colonize the human gut 1 year after birth and accounts for 1%–4%of the total gut microbiota.A.muciniphila specializes in the degradation of mucin(the glycoprotein in mucus)and uses the mucin as the sole source of carbon and nitrogen.A.muciniphila is abundant in the host intestinal mucosal layer,with the greatest abundance in the cecum,where most mucin is produced.[2]Although degradation of mucin is a pathogen-like behavior;A.muciniphila does not show any pathogenicity,it resides only in the outer mucosal layer and does not reach the inner mucosal layer.Recently,several studies have revealed that A.muciniphila has important regulatory effects on gut homeostasis.展开更多
文摘Background:There were few studies on real-world data about autologous hematopoietic stem cell transplantation(auto-HSCT)or allogeneic HSCT(allo-HSCT)in peripheral T-cell lymphoma(PTCL).This study aimed to investigate the clinical outcomes of patients who received auto-HSCT or allo-HSCT in China.Methods:From July 2007 to June 2017,a total of 128 patients who received auto-HSCT(n=72)or allo-HSCT(n=56)at eight medical centers across China were included in this study.We retrospectively collected their demographic and clinical data and compared the clinical outcomes between groups.Results:Patients receiving allo-HSCT were more likely to be diagnosed with stage III or IV disease(95%vs.82%,P=0.027),bone marrow involvement(42%vs.15%,P=0.001),chemotherapy-resistant disease(41%vs.8%,P=0.001),and progression disease(32%vs.4%,P<0.001)at transplantation than those receiving auto-HSCT.With a median follow-up of 30(2–143)months,3-year overall survival(OS)and progression-free survival(PFS)in the auto-HSCT group were 70%(48/63)and 59%(42/63),respectively.Three-year OS and PFS for allo-HSCT recipients were 46%(27/54)and 44%(29/54),respectively.There was no difference in relapse rate(34%[17/63]in auto-HSCT vs.29%[15/54]in allo-HSCT,P=0.840).Three-year non-relapse mortality rate in auto-HSCT recipients was 6%(4/63)compared with 27%(14/54)for allo-HSCT recipients(P=0.004).Subanalyses showed that patients with lower prognostic index scores for PTCL(PIT)who received auto-HSCT in an upfront setting had a better outcome than patients with higher PIT scores(3-year OS:85%vs.40%,P=0.003).Patients with complete remission(CR)undergoing auto-HSCT had better survival(3-year OS:88%vs.48%in allo-HSCT,P=0.008).For patients beyond CR,the outcome of patients who received allo-HSCT was similar to that in the atuo-HSCT group(3-year OS:51%vs.46%,P=0.300).Conclusions:Our study provided real-world data about auto-HSCT and allo-HSCT in China.Auto-HSCT seemed to be associated with better survival for patients in good condition(lower PIT score and/or better disease control).For patients possessing unfavorable characteristics,the survival of patients receiving allo-HSCT group was similar to that in the auto-HSCT group.
基金This study was supported by a grant from the Beijing Natural Science Foundation(No.7162175).
文摘Long noncoding RNAs(lncRNAs)have recently been discovered and are increasingly recognized as vital components of modern molecular biology.Accumulating evidence shows that lncRNAs have emerged as important mediators in diverse biological processes such as cell differentiation,pluripotency,and tumorigenesis,while the function of lncRNAs in the field of normal and malignant hematopoiesis remains to be further elucidated.Here,we widely reviewed recent advances and summarize the characteristics and basic mechanisms of lncRNAs and keep abreast of developments of lncRNAs within the field of normal and malignant hematopoiesis.Based on gene regulatory networks at different levels of lncRNAs participation,lncRNAs have been shown to regulate gene expression from epigenetics,transcription and post transcription.The expression of lncRNAs is highly cell-specific and critical for the development and activation of hematopoiesis.Moreover,we also summarized the role of lncRNAs involved in hematological malignancies in recent years.LncRNAs have been found to play an emerging role in normal and malignant hematopoiesis,which may provide novel ideas for the diagnosis and therapeutic targets of hematological diseases in the foreseeable future.
基金the grants from the National Natural Science Foundation of China(Nos.81973096 and 81502801)the Jiangsu Province Natural Science Foundation(No.BK20201354).
文摘Akkermansia muciniphila(A.muciniphila),a type of Gram-negative anaerobe,was first isolated and identified from the feces of a healthy Caucasian woman at Wageningen University in 2004.[1]It can stably colonize the human gut 1 year after birth and accounts for 1%–4%of the total gut microbiota.A.muciniphila specializes in the degradation of mucin(the glycoprotein in mucus)and uses the mucin as the sole source of carbon and nitrogen.A.muciniphila is abundant in the host intestinal mucosal layer,with the greatest abundance in the cecum,where most mucin is produced.[2]Although degradation of mucin is a pathogen-like behavior;A.muciniphila does not show any pathogenicity,it resides only in the outer mucosal layer and does not reach the inner mucosal layer.Recently,several studies have revealed that A.muciniphila has important regulatory effects on gut homeostasis.
